CAS号:167354-41-8
品名:(6R,7R)-7-[[2-[2-(氨基甲基)苯基]乙酰]氨基]-3-[[1-(羧甲基)四唑-5-基]硫甲基]-8-氧代-5-硫杂-1-氮杂双环[4.2.0]辛-2-烯-2-羧酸(2R)-1-{4-[(1aR,6r,10bS)-1,1-Difluoro-1,1a,6,10b-tetrahydrodibenzo[a,e]cyclopropa[c]cyclohepten-6-yl]piperazin-1-yl}-3-(quinolin-5-yloxy)propan-2-ol
中文别名:(2R)-1-{4-[(1AR,6R,10BS)-1,1-二氟-1,1A,6,10B-四氢二苯并[A,E]环丙并[C]环庚烯-6-基]哌嗪-1-基}-3-(喹啉-5-基氧基)丙-2-醇;唑喹达;ZOSUQUIDAR;
英文别名:Zosuquidar;Unii-ab5K82X98y;Zosuquidar[inn];
分子式:C32H31F2N3O2
分子量:527.604
精确质量:527.238
Psa:48.83
UNII号:AB5K82X98Y
密度:1.36g/cm3
沸点:690.5ºC at 760mmHg
闪点:371.4ºC
折射率:1.691
简介:Zosuquidarisanexperimentalantineoplasticdrugcurrentlyunderdevelopment.IthascompletedPhase3clinicaltrialsintheUnitedStates.ItinhibitsP-glycoproteins.Otherdrugswiththismechanismincludetariquidarandlaniquidar.P-glycoproteinsaretrans-membraneproteinsthatpumpforeignsubstancesoutofcellsinanATPdependentfashion.CancersoverexpressingP-glycoproteinsareabletopumpouttherapeuticmoleculesbeforetheyareabletoreachtheirtarget,effectivelymakingthecancermulti-drugresistant.ZosuquidarinhibitsP-glycoproteins,inhibitingtheeffluxpumpandrestoringsensitivitytochemotherapeuticagents.